Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/32898

Registo completo
Campo DCValorIdioma
dc.contributor.authorSantos, Filipa Moraispor
dc.contributor.authorGonçalves, Vera M.por
dc.contributor.authorPinheiro, Sílviapor
dc.contributor.authorVieira, André Filipepor
dc.contributor.authorParedes, Joanapor
dc.contributor.authorSchmitt, Fernando C.por
dc.contributor.authorBaltazar, Fátimapor
dc.contributor.authorPinheiro, Célinepor
dc.date.accessioned2015-01-15T15:10:46Z-
dc.date.available2015-01-15T15:10:46Z-
dc.date.issued2014-
dc.identifier.issn1351-0088por
dc.identifier.urihttps://hdl.handle.net/1822/32898-
dc.descriptionThis is linked to the online version of the paper at: http://dx.doi.org/10.1530/ERC-13-0132.-
dc.description.abstractThe tumour microenvironment is known to be acidic due to high glycolytic rates of tumour cells. Monocarboxylate transporters (MCTs) play a role in extracellular acidification, which is widely known to be involved in tumour progression. Recently, we have described the upregulation of MCT1 in breast carcinomas and its association with poor prognostic variables. Thus, we aimed to evaluate the effect of lactate transport inhibition in human breast cancer cell lines. The effects of a-cyano-4-hydroxycinnamate, quercetin and lonidamine on cell viability, metabolism, proliferation, apoptosis, migration and invasion were assessed in a panel of different breast cancer cell lines. MCT1, MCT4 and CD147 were differently expressed among the breast cancer cell lines and, as expected, different sensitivities were observed for the three inhibitors. Interestingly, in the most sensitive cell lines, lactate transport inhibition induced a decrease in cell proliferation, migration and invasion, as well as an increase in cell death. Results were validated by silencing MCT1 expression using siRNA. The results obtained here support targeting of lactate transport as a strategy to treat breast cancer, with a special emphasis on the basal-like subtype, which so far does not have a specific molecular therapy.por
dc.description.sponsorshipThis work was supported by the Fundação para a Ciência e a Tecnologia (FCT) grant ref. PTDC/SAU-FCF/104347/2008, under the scope of ‘Programa Operacional Temático Factores de Competitividade’ (COMPETE) of ‘Quadro Comunitário de Apoio III’ and co-financed by the Fundo Europeu De Desenvolvimento Regional (FEDER).por
dc.language.isoengpor
dc.publisherSociety for Endocrinologypor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876-PPCDTI/104347/PT-
dc.relation.ispartofhttp://dx.doi.org/10.1530/ERC-13-0132-
dc.rightsopenAccesspor
dc.subjectBreastpor
dc.subjectMolecular biologypor
dc.subjectCarcinomapor
dc.titleDifferential sensitivities to lactate transport inhibitors of breast cancer cell linespor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttp://erc.endocrinology-journals.org/cgi/pmidlookup?view=long&pmid=24174370por
sdum.publicationstatuspublishedpor
oaire.citationStartPage27por
oaire.citationEndPage38por
oaire.citationIssue1por
oaire.citationTitleEndocrine-Related Cancerpor
oaire.citationVolume21por
dc.date.updated2015-01-14T17:00:50Z-
dc.identifier.doi10.1530/ERC-13-0132-
dc.identifier.pmid24174370por
dc.subject.wosScience & Technologypor
sdum.journalEndocrine-Related Cancerpor
Aparece nas coleções:ICVS - Artigos em revistas internacionais / Papers in international journals

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
morais-santos f_endocr relat cancer 2014 posp.pdf3,75 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID